Arcus Biosciences, Inc.
NYSEArcus Biosciences enters the stretch before its June 11 earnings report carrying two conflicting signals: a fresh clinical collaboration with Bristol Myers Squibb that validates its HIF-2α inhibitor, casdatifan, and a short base that has quietly rebuilt 8% in a single week. Short sellers have added meaningfully to their positions. Short interest climbed to roughly 9% of the free…
RCUS cost to borrow surges to 0.52% — up 726% in one week — after recent biotech analyst upgrades.
Snapshot as of 3 Jun 2026
Arcus Biosciences enters the stretch before its June 11 earnings report carrying two conflicting signals: a fresh clinical collaboration with Bristol Myers Squibb that validates its HIF-2α inhibitor, casdatifan, and a…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RCUS — free to start on ORTEX.
Sign up for free →Open RCUS on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live RCUS data →